[Cardioprotective effect of combined use of coenzyme Q9 and cyclohexyladenosine in ischemia, reperfusion and acute myocardial infarction].
Effects of coenzyme Q9 (25 mg/kg), N6-cyclohexyl adenosine (CHA, 100 micrograms/kg) and their combination were compared in rats with short-term or permanent ligation of the left coronary artery. The following parameters were evaluated in three series of experiments: 1) incidence and duration of ventricular fibrillation and tachycardia during coronary occlusion (10 min) and consecutive reperfusion (5 min); 2) contractility and electrical stability of the heart (ventricular fibrillation threshold) in animals with 2-day myocardial infarction; 3) ischemic myocardial mass after coronary occlusion (5 min) and necrotic tissue mass in 2-day myocardial infarction. The rats were given oral drugs 5 days and 2 hours before the study. All the experiments were performed in open-chest anesthetized (nembutal, 50 mg/kg) rats exposed to ventilation at room air. Both the coenzyme Q9 and CHA significantly reduced the incidence and duration of coronary occlusion and reperfusion arrhythmias, prevented cardiac contractile depression (heart rate.developed pressure) and increased ventricular fibrillation threshold). The effect of coenzyme Q9 was more marked than that of CHA. Coenzyme Q9 substantially reduced necrotic tissue mass while CHA diminished ischemic tissue mass. At the same time the total cardioprotective action of the Q9 + CHA combination was more pronounced than that of them used alone.
F Z
FZ
Meerson
V I
VI
Vovk
L M
LM
Belkina
O M
OM
Pozdniakov
M E
ME
Evsev'eva
E A
EA
Obol'nikova
G I
GI
Samokhvalov
V V
VV
Slobodianik
D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006324:Heart Arrest, Induced; D008297:Male; D009203:Myocardial Infarction / Q000601:surgery*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D051381:Rats; D011919:Rats, Inbred Strains; D014451:Ubiquinone / Q000008:administration & dosage*
D014451:Ubiquinone; C027513:N(6)-cyclohexyladenosine; D000241:Adenosine; C030571:ubiquinone 9
Kardioprotektornyĭ éffekt sochetannogo primeneniia koénzima Q9 i tsiklogeksiladenozina pri ishemii, pererfuzii i ostrom infarkte miokarda.